BioCentury
ARTICLE | Product Development

Myo my

Why omecamtiv mecarbil's cardiac function data could suggest better outcomes

November 16, 2015 8:00 AM UTC

Phase II readouts showing that omecamtiv mecarbil improves cardiac output and physiology could translate into better outcomes and quality of life for chronic heart failure patients, if Amgen Inc. and Cytokinetics Inc. decide to move into Phase III trials.

While the treatment landscape in CHF is changing thanks to newly approved agents, the early data reported at the American Heart Association (AHA) meeting on Nov. 8 in Orlando also suggest omecamtiv mecarbil could safely be used as part of a combination...